Models for predicting effective HIV chemoprevention in women

Keyphrases

• Chemoprevention 100%
• Maraviroc 100%
• Tenofovir 80%
• TZM-bl Cells 80%
• Tissue Explants 60%
• HIV Prevention 40%
• HIV Infection 40%
• Tissue Model 40%
• Emax Model 40%
• Viral 20%
• Tenofovir Disoproxil Fumarate 20%
• Clinical Investigation 20%
• Antiretroviral 20%
• Quantitative PCR 20%
• Active Metabolite 20%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 20%
• Drug Efficacy 20%
• Tissue Concentration 20%
• Single Oral Dose 20%
• Predictive Ability 20%
• Chemoprophylaxis 20%
• Concentration Data 20%
• Cell Concentration 20%
• Vaginal Tissue 20%
• Effective Concentration 20%
• Dosing Strategy 20%
• Luciferase Reporter Assay 20%
• Viral Challenge 20%
• Systematic Comparison 20%
• Spliced RNA 20%
• Tenofovir Diphosphate 20%
• Vaginal Explants 20%
• Objective Model 20%
• Tissue Drug Concentration 20%
• In(III) 20%
• Explant Model 20%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Tenofovir 100%
• Maraviroc 100%
• Clinical Study 60%
• Human Immunodeficiency Virus Infection 40%
• Drug Concentration 20%
• Chemoprophylaxis 20%
• Tenofovir Disoproxil 20%
• Active Metabolite 20%
• Luciferase 20%